Literature DB >> 11930310

Seroprevalence and coinfection with herpes simplex virus type 1 and type 2 in the United States, 1988-1994.

Fujie Xu1, Julia A Schillinger, Maya R Sternberg, Robert E Johnson, Francis K Lee, Andre J Nahmias, Lauri E Markowitz.   

Abstract

Seroprevalence of and coinfection with herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in the United States were analyzed by use of data from a nationally representative survey (National Health and Nutrition Examination Survey III, 1988-1994). Evidence was explored for possible protection by prior HSV-1 infection against infection and clinical disease with HSV-2. Overall, 27.1% of persons aged > or =12 years were seronegative for HSV-1 and HSV-2; 51.0% were seropositive for HSV-1 only, 5.3% for HSV-2 only, and 16.6% for both HSV-1 and HSV-2. The seroprevalence of HSV-2 was higher in persons with HSV-1 antibody. Approximately 76% of persons who had HSV-2 antibody also had HSV-1 antibody. Persons seropositive for HSV-2 only reported a history of genital herpes more frequently (16.2%) than persons seropositive for both HSV-1 and HSV-2 (5.9%). The seroprevalence of HSV-1 and age at infection may influence the epidemiology of clinical genital herpes, even if prior HSV-1 infection does not prevent HSV-2 infection.

Entities:  

Mesh:

Year:  2002        PMID: 11930310     DOI: 10.1086/340041

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  77 in total

1.  Performance and use of a ribonucleotide reductase herpes simplex virus type-specific serological assay.

Authors:  S Q Wales; C C Smith; M Wachsman; G Calton; L Aurelian
Journal:  Clin Diagn Lab Immunol       Date:  2004-01

2.  Molecular characterization of antigen B2 subunit in two genotypes of Echinococcus granulosus from Indian bubaline isolates, its stage specific expression and serological evaluation.

Authors:  D Pan; A K Bera; S Bandyopadhyay; S Das; T Rana; S K Das; S Bandyopadhyay; B Manna; D Bhattacharya
Journal:  Mol Biol Rep       Date:  2010-09-18       Impact factor: 2.316

Review 3.  [Genital herpes].

Authors:  C J Adam; M Staehler; W Khoder; C Stief
Journal:  Urologe A       Date:  2006-12       Impact factor: 0.639

4.  In Vitro and In Vivo Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection.

Authors:  James Hopkins; Tejabhiram Yadavalli; Rahul Suryawanshi; Farreh Qatanani; Ipsita Volety; Ram Koganti; Aqsa Iqbal; Deepak Shukla
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

5.  Herpes virus antibodies seroprevalence in children with autoimmune thyroid disease.

Authors:  Dimitrios Thomas; Feneli Karachaliou; Konstantina Kallergi; Elpis Vlachopapadopoulou; Georgia Antonaki; Fotini Chatzimarkou; Aspasia Fotinou; Philippos Kaldrymides; Stefanos Michalacos
Journal:  Endocrine       Date:  2008-05-13       Impact factor: 3.633

Review 6.  Genome editing and the next generation of antiviral therapy.

Authors:  Daniel Stone; Nixon Niyonzima; Keith R Jerome
Journal:  Hum Genet       Date:  2016-06-08       Impact factor: 4.132

7.  Decreased reactivation of a herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) mutant using the in vivo mouse UV-B model of induced reactivation.

Authors:  Lbachir BenMohamed; Nelson Osorio; Ruchi Srivastava; Arif A Khan; Jennifer L Simpson; Steven L Wechsler
Journal:  J Neurovirol       Date:  2015-05-22       Impact factor: 2.643

Review 8.  Biologic interactions between HSV-2 and HIV-1 and possible implications for HSV vaccine development.

Authors:  Joshua T Schiffer; Sami L Gottlieb
Journal:  Vaccine       Date:  2017-09-25       Impact factor: 3.641

9.  Coinfection Dynamics of Two Diseases in a Single Host Population.

Authors:  Daozhou Gao; Travis C Porco; Shigui Ruan
Journal:  J Math Anal Appl       Date:  2016-04-19       Impact factor: 1.583

10.  Historical correlates of genital herpes simplex virus type 2 infection in men attending an STD clinic.

Authors:  J M Sizemore; F Lakeman; R Whitley; A Hughes; E W Hook
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.